Diabetes melitus (DM) merupakan penyakit tidak menular dengan insidensi terus meningkat setiap tahunnya. Salah satu komplikasi DM tersering adalah nefropati diabetik yang ditandai dengan albuminuria. Sodium glucose co-transporter (SGLT-2) inhibitor merupakan golongan obat antidiabetik yang bersifat insulin independen dan diharapkan menurunkan kejadian kerusakan fungsi ginjal. Kurangnya penelitian dan informasi obat golongan ini di Indonesia menyebabkan peneliti melakukan penelitian dengan tujuan mengetahui efektivitas pemberian obat golongan SGLT-2 inhibitor pada pasien DM tipe 2 terhadap penurunan kejadian albuminuria. Metode yang digunakan dalam penelitian ini adalah scoping review, dengan bahan penelitian artikel dari jurnal internasional yang memenuhi kriteria inklusi dan eksklusi. Artikel ini kemudian diseleksi menggunakan diagram PRISMA dengan mempertimbangkan Population (DM tipe 2), Intervention (pemberian SGLT-2 inhibitor), Comparison (plasebo atau anti diabetik lain), Outcome (penurunan albuminuria), Study (RCT dan Cohort retrospective). Didapatkan dari 13 artikel bahwa obat SGLT-2 inhibitor yang digunakan bervariasi yaitu canagliflozon (6), empagliflozin (3), dapagliflozin (2), ertugliflozin (2), dan yang tersering digunakan adalah canagliflozin ditemukan pada 6 artikel (50%). Golongan obat SGLT-2 inhibitor memiliki kecenderungan yang sama, dapat ditoleransi dengan baik dan efektif dalam menurunkan kejadian albuminuria melalui mekanisme perubahan hemodinamik ginjal, dengan urin albumin-kreatinin rasio (UACR) sebagai parameter. Scoping ReviewSGLT-2 Inhibitors Effective to Reduce Albuminuria in Type 2 Diabetes Mellitus Diabetes mellitus (DM) is a non-communicable disease with an increasing incidence every year. One of the most common complications of DM is diabetic nephropathy which is characterized by albuminuria. Sodium-glucose co-transporter (SGLT-2) Inhibitors is a class of anti-diabetic drugs that are insulin-independent and expected to reduce the incidence of impaired kidney function. The aim of this study was to ensure the effectiveness of SGLT-2 inhibitor drug administration in type 2 DM patients to reduce the incidence of albuminuria. The method used is scoping review, with research articles from international journals sorted by the inclusion and exclusion criteria. These articles was selected using the PRISMA diagram by considering Population (DM type 2), Intervention (administration of SGLT-2 inhibitors), Comparison (placebo or other anti-diabetic), Outcome (decreased albuminuria), Study (RCT and retrospective cohort). It was obtained from 13 articles that the SGLT-2 inhibitor drugs used varied, canagliflozon (6), empagliflozin (3), dapagliflozin (2), ertugliflozin (2), and the most commonly used was Canagliflozin found in 6 articles (50%). The SGLT-2 inhibitor class of drugs has the same tendency, well-tolerated, and effective in reducing the incidence of albuminuria through the mechanism of renal hemodynamic changes, with urine albumin-to-creatinine ratio (UACR) as a parameter.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.